ArticleMicroorganisms2020
A Frameshift Mutation in
Article in Microorganisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Evolutionary dynamics and research hotspots of phage applications againstFrontiers in microbiology · 2026Pooled it
- Phenotypic heterogeneity and genetic mechanisms of phage resistance in hypervirulent carbapenem-resistantVirulence · 2026Article
- The Single Amino Acid Substitution in WcaJ(Ser332Leu) Promotes Hypervirulent Klebsiella Pneumoniae Resistant to Bacteriophage and Virulence Attenuated.Probiotics and antimicrobial proteins · 2026Article
- Phage resistance bidirectionally altered antibiotic susceptibility in Klebsiella pneumoniae via galE mutation.International journal of antimicrobial agents · 2026Article
- Investigation of the therapeutic efficacy and resistance mechanisms of lytic phages targeting ST218 KL57 CR-hvKP.mSystems · 2026Article
- Phylogenetic diversification and fitness trade-offs of TetA variants in mediating eravacycline resistance inAntimicrobial agents and chemotherapy · 2026Article
- Article
- Phages adapt to recognize an O-antigen polysaccharide site by mutating the "backup" tail protein ORF59, enabling reinfection of phage-resistantEmerging microbes & infections · 2025Article
- Identification of the Genetic Basis of Phage Resistance in Sequentially Generated Phage-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Evolutionary responses of Escherichia coli to phage pressure: insights into mucoidy and colanic acid overexpression.BMC genomics · 2025Article
- Phage therapy for Klebsiella pneumoniae: Understanding bacteria-phage interactions for therapeutic innovations.PLoS pathogens · 2025Review
- Potential of a phage cocktail in the treatment of multidrug-resistant Klebsiella pneumoniae pulmonary infection in mice.BMC microbiology · 2025Article
- Synergistic action of mucoactive drugs and phages againstMicrobiology spectrum · 2025Article
- Capsule mutations serve as a key strategy of phage resistance evolution of K54 hypervirulent Klebsiella pneumoniae.Communications biology · 2025Article
- Design and regulation of engineered bacteria for environmental release.Nature microbiology · 2025Review
- "Sichuanvirus", a novel bacteriophage viral genus, able to lyse carbapenem-resistant Klebsiella pneumoniae.BMC microbiology · 2025Article
- Challenges and opportunities of phage therapy forApplied and environmental microbiology · 2024Review
- A tradeoff between bacteriophage resistance and bacterial motility is mediated by the Rcs phosphorelay inMicrobiology (Reading, England) · 2024Article
- Host immunity involvement in the outcome of phage therapy against hypervirulentAntimicrobial agents and chemotherapy · 2024Article
- Capsules and their traits shape phage susceptibility and plasmid conjugation efficiency.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage therapy is a potential and promising avenue for controlling the emergence and spread of multidrug-resistant (MDR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.